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APV by acetylcholine (10 microglkgimin) injection into mAA. The endothelium-indepen- 
dent vascular function (EIDVF) was determmed as a ratio of basal to peak of APV by 
nitroglycerin (10 microglkglmm) injection Into mAA. Simultaneously, the plasma isopros- 
tame FPalpha-Ill was measured by ELISA kit (Oxford Biomedical). Results: The infusion 
of isoprostane F2alpha-Ill significantly attenuate EDVF in CH rabbits (1.8 iO.3 vs. 2.3 
kO.1; p<O.Ol). The treatment by ramatroban can improve the EDVF in CH rabbits (3.8 
i0.2 vs. 2.3 +O.l; p<O.Ol). There was no significant difference in the EIDVF among the 
four groups. The plasma isoprostane FPalpha-Ill levels in CH or CH + IP rabbits was sig- 
nificant higher than NL rabbits (488 244. 858 *59 vs. 256 *17 ng/ml,both ~~0.01). Con- 
clusion: This study suggested that isoprostane FPalpha-Ill synthesis induced by 
experimental hypercholesterolemia may be due to impaired endothelial function in rab- 
bits. This effect may be due to TXAP receptor stimulation. 
1155-150 Comparison of Effect of Thiazolidinediones on 
Atherosclerosis in Apolipoprotein E-Deficient Mice 
Masaaki Mivata Qi Gong, Sadatoshl Biro, Hideyuki Eta, Koii Orihara, Tow Obata. 
Shinichi Minagoe. Chuwa Tei, Kagoshima University, Kagoshima, Japan 
Background: Thiazolidinediones are peroxisome proliferator-activated receptor-gamma 
agonists and are used to improve insulin resistance in type II diabetes mellitus. It is con- 
troversial whether thiazolidinediones promote or inhibit atherosclerosis in viva. The pur- 
pose of this study is to compare the effect of thiazolidinediones on atherosclerosis in 
apolipoprotein E (apoE)-deficient mice. Methods At 4 weeks of age, male apoE-defi- 
cient mice were weaned from mother and fed a powdered F-2 chow diet alone (control 
group, n=7) or F-2 chow diet with 0.2% troglitazone added (troglitazone group, n=7). with 
0.02% pioglitazone added (pioglitazone group, n=7), or with 0.002% rosiglitazone added 
(rosiglitazone group, n=7). The dose of drugs was determined by the clinical dosage of 
each drug. At 24 weeks of age, mice were sacrificed and atherosclerotic lesions in the 
aortic root were measured by a quantitative assay. Results There were no significant 
differences among 4 groups in body weight, total cholesterol. fasting blood sugar or 
HbAlc levels at 24 weeks. The atherosclerotic lesion of troglitazone group was signifi- 
cantly smaller than that of control group (control; 0.235iO.052 mm2 vs. troglitazone: 
0.170+0.057 mm’, p&05), in contrast, that of pioglitazone and rosiglitazone groups 
showed no significant difference compared to control group (pioglitazone; 0.260+0.081 
m&, rosiglitazone; 0.244*0.058 mni$ Troglitazona IS reported to be a radical-scaven- 
ger, because it has a similar structure wth vitamin E. Therefore, antioxidant actwity was 
determined by measuring plasma levels of isoprostane (8.epi prostaglandine F&x: 8epi 
PGF2a) with gas chromatography-mass spectrometry selected ion monitoring. The 
plasma 8-epi PGFZ& level of the trogl&szone group was significantly lower than those of 
other groups (troglitazone; 186+74 pglml vs. control; 353rll9, pioglitazone; 410*216, or 
rosiglitazone; 423~207. ~~0.05). Conclusion: Troglitazone with accessory antioxidant 
activity reduces isoprostane generation and the atherosclerosis in apoE-deficient mice, 
whereas pioglitazone and roslglitazone do not. 
1155-148 Differential Effects of Cyclooxygenase and Nitric Oxide 
Inhibition on Endothelium-Dependent Responses in 
Coronary Arteries From Juvenile and Adult Male Pigs 
Ritu Chatrath, Karen L. Ronningen, Peter LaBreche, Muthuvel Jayachandran, Margarita 
P. Bracamonte. Virginia M. Miller, Mayo Clinic Rochester, Rochester, MN 
Background: Experiments were designed to determine effects of puberty on endothe- 
lium-dependent responses I” coronary arteries of juvenile and adult males. 
Methods: Rings from right coronary artery with and without endothelium from 8 juvenile 
(2-3 mo: testosterone 67*17 mg/dL) and 8 adult (5-6 mo; testosterone 625+184 mg/dL) 
male pigs were suspended in organ chambers for measurement of isometric force. Dur- 
ing contractions to prostaglandin Fpa, cumulative concentration response curves to UK- 
14. 304 (a-adrenergic agonist) and bradykinin (BK) were obtained in the absence and 
presence of either indomethacin or indomethacm plus ~-monomethyl-L-arginine (L- 
NMMA) to inhibit cyclooxygenase and nitric oxide synthase, respectively. Blood was col- 
lected for measurement of nitric oxide (NO). 
Results: Plasma NO was significantly higher in juvenile compared to adult males 
(48.7k28.3 vs. 18.6*7.2 kmol/L, p<O.OOOl). UK-14, 304 caused similar concentration- 
dependent relaxations only in rings with endothelium from juvenile and adult pigs. With 
indomethacin, relaxations were significantly enhanced in arteries from adult pigs (EC, = 
7.9eO.27 -log mol/L), and reduced I” arteries from juvenile pigs (EC, = 6.7+0.37 -log 
mol/L) (p&023). L-NMMA significantly inhibited relaxations in arteries from both groups. 
Relaxations to BK also were similar in rings with endothelium from juvenile and adult 
pigs. In arteries from juvenile but not adult pigs, indomethacin caused a rightward shift of 
the dose response cwve (p=O.O8). Whereas, L-NMMA in the presence of indomethacin 
caused significant nghtward shift of dose-response curve (p=O.O3) in arteries from adult 
but not juvenile pigs. 
Conclusion: Endothelium-dependent responses are selectively modulated by cyclooxy- 
genase and nitric oxide inhibition in coronary artenes from male pigs. At immaturity, inhi- 
bition of cyclooxygenase reduces relaxations which is reversed with maturation. Nitric 
oxide is reduced with maturity and associated with relaxations to BK. Shifts from inhibi- 
tory tc contractile prostanolds and decreases in plasma NO may be related to production 
of testosterone 
1155-149 Short-Term Therapy With Gatifloxacin or Azithromycin 
Prevents the Acceleration of Atherosclerosis After 
Infection With Chlamydia Pneumoniae in a Rabbit 
Model but Does Not Eradicate the Organism From 
Plaque 
Heath U. Jones, Joseph B. Muhlestein. Tobin H. Llm. Jason Jensen, Robert R. Pearson, 
Beniamm D. Home. Mahtab Sohrevardl. John F. Carlauist. Jeffrev L. Anderson. LDS 
Hospital, Salt Lake City UT, Unwersity of Utah, Salt Lake City, UT 
Background: Chkmydia pneumoniae (Cpn) IS associated with atherosclerosis in human 
and animal studies, and short term (~3 months) antibiotic therapy has prevented Cpn- 
induced atherosclerosis in rabbits. However, short term antibiotic therapy has not dem- 
onstrated lasting clinical benefit in recent secondary prevention tnals. It is proposed that 
these poor long-term results may be due to inabIlIty of the antlbiotic to eradicate the 
organism. Both azthromycin (A) and gatifloxacln (G) are agents presently bemg tested 
for the secondary prevention of atherosclerosis. Whether either 1s able to eradicate Cpn 
from atherosclerotic plaque IS unknown. 
Methods: Forty-five rabbits received a 0.25% dietary supplement of cholesterol and were 
randomized 2:1 to Cpn infection or placebo and then randomized 1 :I :1 to A 30 mglkgl 
day X 1 week followed by 30 mg/kg twice weekly for 6 weeks, G 50 mg/kg/day for 7 
weeks, 01 placebo. One uninfected rabbit died spontaneously, and the rest were eutha- 
nized 3 months after initial infection. Blinded sections of the aorta were examined to cal- 
culate plaque percent area stenosis (PAS) (plaque area / total area within ,the internal 
elasbc lamina) The presence of Cpn within aortlc sections was evaluated by direct 
lmmunofluorescence (DIF) (Bartels). 
Results: PAS was greater for infected, untreated arteries (39*12%) than the other groups 
(non-infected = 21+12%; infected + A = 20+11%: infected + G = 22+14%, all p-values 
co.05 vs. infected-untreated). DIF was positive within the aortas of 0114 non-infected, 81 
10 infected/untreated, 400 infected/A, and 5/10 infected/G rabbits. 
Conclusion: Although a seven-week course of A or G significantly prevented Cpn- 
induced acceleration of atherosclerosis in the rabbit, neither was able to eradicate the 
organism by three months. This finding may help to explain the disappointing long-term 
results in recent clinical tnals. We propose that longer or different anti-mwobial therapy 
may be required to eradicate Cpn and provide lasting clinical benefit in the settmg of pri- 
mary or secondary prevention for atherosclerosis. 
1155-151 The Cardiac Peptide BNP Is Superior to ANP and the 
Renally Derived Peptide Urodilatin in Enhancing Renal 
Function in Overt Experimental Congestive Heart 
Failure 
Homq H. Chen, Alessandro Cataliotti, John A. Schirger, Gail Harty, John C. Burnett, Jr., 
Mayo Clinic and Foundation, Rochester, MN 
BACKGROUND: Recent studies have reported that improving renal function IS the most 
important predictor of suwival in congestive hearl failure (CHF). A hallmark of overt CHF 
is attenuated cGMP production to ANP with renal resistance. BNP is FDA approved for 
the management of acute CHF and is synthesized and released by cardiomyocytes. 
Urodilatin (Uro) is from the kidney and has been isolated from human urine with an amino 
acid (AA) sequence identical to ANP except for N-terminal extension of four AA residues. 
Studies have reported that exogenous Uro results III greater renal effects as compared to 
ANP but to date no comparison has been made with BNP nor ANP to BNP. METHODS: 
We determined the cardiorenal and humoral actions of equimolar infusion of (10 pmollkgl 
m(n) ANP (n=6), BNP (n=5) and Uro (n=6) in 3 separate group of dogs with rapid ventric- 
ular pacing induced overt CHF (240 bpm for 10 days)RESULTS: BNP resulted in 
increases in urinary sodium excretion (UNaV) (2.2* 0.7 to 164* 76 ~qlmln, ~~0.05) and 
glomerular filtration rate (GFR) (27+ 4 to 52* 11 ml/min, p=O.O5) which were greater as 
compared to Uro ( ~~0.05 BNP vs Uro), while ANP did not increase in either UNaV 01 
GFR. The increase in plasma cGMP (25+ 2 to 38+ 2 pmol/ml. p&O5 ) and urinary cGMP 
excretion with BNP (1618* 151 to 6124i 995 pmol/min, ~~0.05) wan? similar to Uro, 
however there was no significant change with ANP. Cardiac flllmg pressures were 
reduced similarly in all three groups. CONCLUSION: In this model of experimental overt 
CHF. infusion of BNP oroduced water increases III UNaV and GFR as compared to 
Uro, while ANP did not result in significant changes. These favorable renal effects were 
associated with increases in both clasma cGMP and urinarv cGMP excretion. which 
were similar with BNP and Uro, however were unchanged with ANP. Thts study demon- 
strates the superionty of BNP to Uro and ANP in enhancing renal function in severe 
experlmental CHF. These studies also support the conclusion that in CHF, renal resis- 
tance to natriuretic peptides in increasing rank order is ANP>Uro>BNP. These results 
may have clinical implications when considering the therapeutic efficacy of these pep- 
tides in the management of overt CHF. 
POSTER SESSION 
1156 Lipids and Risk Factors 
Tuesday, April 01, 2003, 9:00 a.m.-l 1:OO a.m 
McCormick Place, Hall A 
Presentation Hour: 10:00 a.m.-l 1:OO a.m. 
1156-117 Prograf Decreases Plasma Cholesterol in Heart 
Transplant Recipients With Treated but Persisting Mild 
Dyslipidemia: The Canadian Multicenter Randomized 
Trial of Prograf Versus Neoral 
Michel White, on behalf of the Canadian Heart Transplantation Group. Montreal Heart 
Institute. Montreal, PC?, Canada 
Background: Despite optimal use of potent lipid-lowering agents, most heart transplant 
recipients exhibit persisting dyslipidemia not satisfying the current guidelines for high-risk 
patients. We have mitlated a Canadian mulbcenter prospective study of Neoral mainte- 
